Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.26/15532 |
Resumo: | Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS. |
id |
RCAP_4c3057df739332a57a04e1a80e71da2c |
---|---|
oai_identifier_str |
oai:comum.rcaap.pt:10400.26/15532 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosisMitoxantronaCardiotoxicidadeEsclerose múltiplaTerapêuticaFarmáciaMultiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.Springer InternationalRepositório ComumMartins, Diana Mafalda MirandaMatos, CristianoJoaquim, João José Morais, 1969-2016-11-21T12:09:39Z2016-10-20T21:58:20Z2015-01-01T00:00:00Z2015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.26/15532porMartins, Diana Mafalda Miranda; Matos, Cristiano; Joaquim, João José. Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis, Trabalho apresentado em 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ , In 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ - Abstracts, Praga, 2015.1179-1942DOI 10.1007/s40264-015-0346-0info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-05T15:39:24Zoai:comum.rcaap.pt:10400.26/15532Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:15:23.914876Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
title |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
spellingShingle |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis Martins, Diana Mafalda Miranda Mitoxantrona Cardiotoxicidade Esclerose múltipla Terapêutica Farmácia |
title_short |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
title_full |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
title_fullStr |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
title_full_unstemmed |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
title_sort |
Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis |
author |
Martins, Diana Mafalda Miranda |
author_facet |
Martins, Diana Mafalda Miranda Matos, Cristiano Joaquim, João José Morais, 1969- |
author_role |
author |
author2 |
Matos, Cristiano Joaquim, João José Morais, 1969- |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Repositório Comum |
dc.contributor.author.fl_str_mv |
Martins, Diana Mafalda Miranda Matos, Cristiano Joaquim, João José Morais, 1969- |
dc.subject.por.fl_str_mv |
Mitoxantrona Cardiotoxicidade Esclerose múltipla Terapêutica Farmácia |
topic |
Mitoxantrona Cardiotoxicidade Esclerose múltipla Terapêutica Farmácia |
description |
Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-01-01T00:00:00Z 2015-01-01T00:00:00Z 2016-11-21T12:09:39Z 2016-10-20T21:58:20Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.26/15532 |
url |
http://hdl.handle.net/10400.26/15532 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Martins, Diana Mafalda Miranda; Matos, Cristiano; Joaquim, João José. Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis, Trabalho apresentado em 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ , In 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ - Abstracts, Praga, 2015. 1179-1942 DOI 10.1007/s40264-015-0346-0 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer International |
publisher.none.fl_str_mv |
Springer International |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130018521022464 |